The purpose of the study is to determine how well this test can serve as a biomarker for detecting the SDHx mutation by measuring a unique pattern of sugar metabolism in the blood, and to compare the results with standard genetic testing. A biomarker is a measurable sign that can indicate the presence of a disease or a genetic change.

Participants will receive the sugar infusion, have blood drawn at several time points, and then undergo the planned tumor removal surgery. The blood samples will be examined for the specific metabolic pattern, and the findings will be compared with tumor size seen on imaging and with the tissue analysis after surgery. The study follows each person from the infusion through the surgical procedure and a short follow‑up period.

Participants will take the study pill each day for about one year and will attend clinic visits roughly every 12 weeks. During visits, blood samples will be taken and an oral glucose tolerance test will be performed, which involves drinking a sugary solution and measuring how the body handles the sugar. The test will be used to calculate the disposition index, a measure of how well the pancreas releases insulin. Additional laboratory checks will look at the proinsulin-to-C-peptide ratio, levels of chromogranin A, GLP-1 and GIP, as well as the body’s insulin sensitivity and insulin secretion. Immune cells called CD4+/CD8+ T-cell responses in peripheral blood monocytes will also be examined. Throughout the study, participants will wear a sensor for continuous glucose monitoring to track blood sugar levels, time spent in target ranges, and overall glucose variability.

During the trial, participants will take the study medication once daily for about 24 weeks. They will attend regular clinic visits where blood samples are drawn to measure hormone levels and safety checks are performed. The study follows a straightforward schedule of visits and tests, allowing researchers to observe changes in hormone levels over time without requiring any invasive procedures.

The purpose of the study is to determine if starting the GLP-1 therapy enhances the protective effect of the pneumococcal vaccine. Participants are given the vaccine and then either begin treatment with the study medication or continue with usual care (some may receive a placebo). Blood samples are taken a short time after vaccination and again several months later to see how well the immune system has responded, while safety is checked through routine visits and questionnaires.

In simple terms, the researchers measure the level of IgG antibodies, which are proteins that help the body recognize and fight the bacteria. They also look at markers of inflammation (signs that the body is reacting to infection) and count certain immune cells to see if the medication changes their numbers or function. Any side effects or serious health problems related to infection are recorded throughout the study.

The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.

The main aim of the trial is to find out whether either medication can lower the risk of developing new kidney stones and slow the progression of the disease. Participants will be followed for up to two years, with regular clinic visits where blood and urine samples are taken and simple imaging scans are performed to look for stones and assess kidney health. One of the key laboratory measures is the eGFR, which estimates how well the kidneys are filtering waste from the blood.

During the study, researchers will compare the occurrence of kidney stones, changes in kidney function, and overall physical and mental well‑being between the groups receiving the study medicines and those receiving a placebo. The information gathered will help determine if these treatments are useful for preventing stone formation and preserving kidney health in people with this condition.

Participants in the study will receive either the test medication NNC0662-0419, a comparator drug named Ozempic, or a placebo. The study will monitor changes in HbA1c, which is a blood test that shows the average blood sugar levels over the past few months. Additionally, changes in body weight will be observed during the course of the research.

Participants will be assigned to receive either palopegteriparatide, also known as TransCon PTH, through a subcutaneous injection, which is a small needle under the skin, or the standard treatment. The standard treatment consists of alfacalcidol, an active form of vitamin D, and calcium supplements taken orally. This study aims to observe how these different treatments affect daily life, thinking skills, and blood flow within the small vessels of the brain.

During the study, various assessments will be performed to monitor changes. This includes the use of MRI, a medical imaging technique that creates detailed pictures of the inside of the body, to look at the structure of the brain. The research also examines how blood moves through the capillaries, which are the tiny blood vessels that connect larger arteries and veins, to see if the treatment helps improve brain health and overall well-being.

Participants in the study will use an automated insulin delivery system, which is a technology that helps manage insulin levels automatically. During the study, individuals will receive a subcutaneous injection, meaning the medicine is injected just under the skin, before performing moderate exercise. The study examines how these medications affect blood sugar levels while performing continuous exercise approximately 90 minutes after eating a meal.

The treatment being studied is palopegteriparatide, which is administered through subcutaneous injection. This means the medicine is delivered by injecting it into the fatty layer of tissue just under the skin using a pre-filled pen. Participants will receive this medication daily during the course of the study to see how it affects their ability to maintain healthy mineral levels without needing large amounts of supplemental vitamin D or high doses of calcium tablets.

The medication used, glimepiride, belongs to a group of drugs called sulfonylureas. During the study, participants will undergo a process where their medication dose is gradually increased to find an effective amount. Blood sugar levels will be tracked using continuous glucose monitoring, which is a method that involves a small device to measure sugar levels in the body continuously over time. The study will look at how well the sugar levels stay within a healthy target range and how the medication affects overall sugar stability.

The purpose of this study is to see if inhibiting the production of cortisol can help improve blood pressure and blood sugar control. Participants will be assigned to receive either metyrapone or a placebo. During the study, various health measurements will be taken to track changes in hormone levels, weight, and blood sugar levels over several months.

Participants in the study will be assigned to receive either LUM 201 in the form of a capsule or a placebo. During the 12-month period, the study will monitor changes in growth and levels of specific substances in the blood, such as IGF-1, which is a hormone that helps the body grow, and IGFBP-3, a protein that carries these growth hormones through the bloodstream. Height and growth patterns will also be tracked throughout the course of the study.

The purpose of the study is to compare how much of the medication is absorbed into the bloodstream from different capsule formulations. Participants will take a single dose of each capsule type while fasting, meaning they will not eat for several hours before taking the medicine, and the study will follow a simple schedule where each dose is given at separate times.

Researchers will watch for any adverse events, which are side effects or unwanted reactions, and will record how often they occur and how severe they are, while also measuring how much of the drug reaches the blood to understand its bioavailability.

Participants will receive different versions of the medication in a specific sequence to allow for a direct comparison. During the study, measurements will be taken to track the levels of the hormone in the body and to monitor safety. This includes checking physical health, skin condition, and vital signs, as well as performing an ECG, which is a test that records the electrical activity of the heart. The process involves using the gels under fasting conditions, meaning no food is consumed for a period before the medication is applied.

The purpose of this study is to see if atumelnant is safe and works well in children with congenital adrenal hyperplasia, and whether it can help reduce the amount of glucocorticoid medicine they need to take while keeping their hormone levels normal. The study is divided into three parts. In Part A, participants will receive atumelnant for eight weeks to check how safe it is and to measure changes in a hormone called androstenedione, which is one of the androgens that becomes too high in people with this condition. In Part B, which lasts twenty-eight weeks, the study will look at whether atumelnant allows doctors to lower the daily dose of glucocorticoid medicine while keeping androstenedione levels normal. Some participants may receive placebo. In Part C, which is a long-term extension, participants who completed Part A or Part B can continue treatment to see how atumelnant works over a longer period of time.

During the study, participants will have regular visits where doctors will check their hormone levels through blood tests, monitor their safety, and measure how much medicine is in their blood. The study will also look at changes in another hormone called 17-hydroxyprogesterone, which is also elevated in people with congenital adrenal hyperplasia. The doctors will carefully watch for any side effects and see how well participants tolerate the medicine. Throughout the study, participants will continue to take their regular replacement hormone medicines, and doctors will adjust the doses as needed based on how the participant responds to atumelnant.

The purpose of this study is to evaluate the safety and how well the body tolerates multiple doses of ALN-4324 in patients with Type 2 Diabetes Mellitus. The study will also look at how effective the medication is in controlling blood sugar and how the body processes the medication. Safety will be checked by monitoring any unwanted effects, measuring vital signs like blood pressure and heart rate, performing heart tests called ECGs, and doing blood tests in the laboratory.

The study is divided into two parts and will involve giving either ALN-4324 or placebo to participants. In one part, healthy volunteers who are overweight or have obesity will receive a single dose, while in the other part, patients with Type 2 Diabetes Mellitus who are overweight or have obesity will receive multiple doses over time. During the study, doctors will measure changes in a blood test called HbA1c, which shows average blood sugar levels over several months, and will also look at how the body responds to sugar by measuring insulin and glucose levels. Blood samples will be taken to measure how much ALN-4324 is in the body. The study will last for several months, and participants will need to attend regular visits for monitoring and testing.

The purpose of the study is to find out if atorvastatin can prevent the development of active Graves ophthalmopathy in patients who have just been diagnosed with Graves’ disease. Participants will take atorvastatin tablets by mouth for a period of 12 months. The maximum daily dose will be 40 milligrams. During the study, patients will be monitored at several time points over 18 months to check if they develop eye problems and to measure the activity level of any eye inflammation using a scoring system. The study will also look at how the treatment affects quality of life and measure certain antibodies in the blood that are related to the disease.

Throughout the study period, researchers will collect information about whether patients need additional treatments for eye problems, such as corticosteroids or other medications. Blood samples will be analyzed to look for biological markers that might help predict who will respond well to the treatment. The study will also examine genetic differences between people who respond to atorvastatin and those who do not. Patients will complete questionnaires about their quality of life at the beginning of the study, after 12 months, and after 18 months to see how the treatment affects their daily living and well-being.

The purpose of this study is to find out how these hormone medications affect blood sugar control in women with diabetes who are experiencing menopause symptoms. The study will look at whether using estradiol patches combined with progesterone capsules helps to keep blood sugar levels within a healthy range. During the study, participants will have periods where they receive the hormone treatment and periods where they do not receive treatment. Blood sugar levels will be measured continuously using a monitoring device worn on the body for two weeks at different times during the study.

The study will also look at other health measures, including how well insulin works in the body, changes in blood pressure, cholesterol levels, liver fat content, muscle strength, and various symptoms related to menopause and diabetes. Participants will complete questionnaires about their symptoms, sleep quality, mood, and overall quality of life. Some participants will undergo additional tests such as an MRI scan to measure liver fat and specialized tests to measure how the body responds to insulin. The entire treatment period will last up to 60 months, during which participants will be monitored to see how the hormone treatment affects their diabetes control and overall health.

The purpose of the study is to see how mibavademab affects body weight in people with this genetic form of obesity. The study will measure changes in body weight and Body Mass Index, which is a calculation using height and weight to assess body size. The treatment will be given over a period of up to 52 weeks, with additional follow-up time afterward. During the study, measurements will be taken to see how body weight, waist size, and body fat change over time. Body fat will be measured using a method called DXA, which is a type of scan that shows how much fat is in different parts of the body.

The study will also look at how the treatment affects hunger and eating behaviors by using questionnaires about hyperphagia, which means excessive hunger and overeating. Safety will be monitored throughout the study by tracking any unwanted effects that occur during treatment. Blood samples will be taken to measure the amount of medication in the body and to check whether the immune system creates any reactions to the treatment. This is an open-label study, which means both the participants and the doctors will know what treatment is being given.

The purpose of the study is to find out whether taking magnesium aspartate by mouth for eight days can reduce the occurrence of long-term hypoparathyroidism six months after surgery. Participants will be randomly assigned to receive either the magnesium supplement or placebo, and neither the participants nor the doctors will know which treatment is being given. The magnesium or placebo will be taken starting before the surgery and continuing for several days afterward. During the study, doctors will monitor calcium levels and parathyroid hormone levels in the blood to check how well the parathyroid glands are working.

Throughout the study period, which lasts up to six months after surgery, participants will be checked at different time points to see if they develop hypoparathyroidism and whether they need additional treatments such as calcium or vitamin D supplements. The study will also track any side effects or unwanted reactions to the treatment and ask participants about symptoms they may experience related to low calcium levels. This information will help researchers understand if giving magnesium before and after thyroid surgery can protect the parathyroid glands and prevent complications.

The purpose of this research is to understand how crinecerfont works in the bodies of young children with CAH, including how safe it is and how well they tolerate it. During the study, children will receive the medication for 14 days while continuing their regular hormone replacement treatment. The study will monitor how the medicine moves through their bodies and collect information about any effects they experience.

Throughout the study, researchers will take blood samples to measure the amount of medicine in the children’s bodies. They will also watch for any changes in the children’s health and record any side effects that may occur. This information will help determine if the medication might be suitable for treating young children with CAH in the future.

The purpose of this study is to determine if ALXN2420 can help lower levels of a hormone called IGF-1 in people with acromegaly when combined with standard treatments. The study compares ALXN2420 to placebo, with both being given alongside regular acromegaly medications. The treatment period lasts for 15 weeks, during which participants receive either ALXN2420 or placebo through injections under the skin.

Throughout the study, participants continue their regular acromegaly medications, which are given as injections either into the muscle or under the skin once every four weeks. The study monitors how well the combination of treatments works by measuring hormone levels and tracking any changes in symptoms. Participants also complete questionnaires about their quality of life and overall health during the study period.

The study involves three groups of participants. Some patients will receive Debio 4126 through intramuscular injection, while others will receive a placebo. The third group will receive Debio 4126 in an open-label manner, meaning both the doctor and patient know which treatment is being given. The medication will be administered every 12 weeks, and patients will be monitored for changes in their IGF-1 levels and overall health throughout the study period.

The treatment may also include other medications such as lanreotide for some participants. Throughout the study, doctors will monitor the safety of the treatment by checking various health parameters, including blood tests, vital signs, and the size of the pituitary tumor. They will also evaluate how well patients tolerate the injections by assessing any reactions at the injection site.

During the study, participants take medication for four weeks. For the first two weeks, they take one tablet daily, followed by two tablets daily for the next two weeks. The study is designed so that participants receive both colchicine and placebo at different times, but neither they nor their doctors know which treatment they are receiving at any given time.

The main purpose is to determine if colchicine, when added to regular diabetes care, can help the body use insulin more effectively. The medication is being tested because some people with Type 1 diabetes have inflammation in their body that may make it harder for insulin to work properly. The study measures how well the body responds to insulin during treatment with colchicine compared to treatment with placebo.

The study involves four different groups of participants, with each group receiving one of the treatments mentioned above. The medications are administered over an 8-week period. Triptorelin is given as an injection into the muscle, while both estradiol and testosterone are applied to the skin as gels. Some participants will receive placebo treatment instead of active medication.

During the study, researchers will monitor changes in bone health markers and other body functions. The study will also track changes in various aspects of participants’ health, including hormone levels, quality of life, sleep patterns, and other health indicators. Regular check-ups and blood tests will be performed to ensure participant safety throughout the study period.

During the study, participants will receive either semaglutide or placebo as a subcutaneous injection (an injection under the skin). The treatment will continue for 68 weeks. The medication dose will be gradually increased over time, reaching a maximum daily dose of 2.4 mg.

The study will measure various health indicators including body weight, blood pressure, blood sugar control, and other health markers. Some participants will also undergo additional tests to measure body composition and insulin sensitivity. Throughout the study, participants will need to continue their regular diabetes care and insulin treatment while receiving the study medication.

The purpose of this study is to determine if patients who receive PRRT after complete surgical removal of their tumor have a longer time without cancer recurrence compared to patients who only receive standard monitoring. Participants in this study will be randomly assigned to either receive PRRT (experimental group) or undergo regular surveillance with no additional treatment (control group). Both groups will be monitored for at least 60 months (5 years) to track if and when the cancer might return.

Throughout the study, participants will undergo imaging tests called PET-CT scans that use special tracers to detect if there are any new tumors. They will also complete questionnaires about their quality of life. The study will track side effects of the treatment and measure how long participants remain free of disease and their overall survival rates.

The purpose of this study is to determine if tirzepatide is more effective than placebo in improving ovarian function in women with PCOS who have overweight or obesity. Tirzepatide is a medication that helps regulate blood sugar and can promote weight loss. The study will focus specifically on whether the medication can help normalize menstrual cycles in women with PCOS.

Participants will receive either tirzepatide or placebo through self-injection for 72 weeks (approximately 1.5 years). Throughout the study, researchers will track menstrual cycles, measure hormone levels in the blood, monitor changes in body weight and composition, and assess various health indicators related to metabolism and quality of life. Participants will need to avoid hormonal contraceptives during the study period and use alternative barrier methods for contraception.

The purpose of the study is to evaluate the effects of different doses of vosoritide compared to a placebo over a period of six months. In the long-term phase, the study will compare the effects of vosoritide with human growth hormone (hGH) on children’s height and growth patterns. The study will involve regular assessments of the children’s growth, including changes in height and growth rates, over a period of up to four years.

Participants in the study will receive either vosoritide or a placebo through subcutaneous injections, which means the injection is given under the skin. The study aims to find the most effective dose of vosoritide and to understand its long-term benefits and safety for children with ISS. Regular monitoring will be conducted to track any side effects and to measure changes in growth and development.